Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus

Autor: Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Nanba, Yoichi Nakamura, Satoshi Akagi, Satoru Sakuragi, Taro Minagawa, Yusuke Kawai, Nobuhiro Nishii, Soichiro Fuke, Masaki Yoshikawa, Kazufumi Nakamura, Hiroshi Ito, Tetsuya Sato, Hiroyasu Sugiyama, Michio Imai, Naoki Gotoh, Tomonori Segawa, Toshiyuki Noda, Masatoshi Koshiji
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Drug Administration Schedule
law.invention
Randomized controlled trial
law
Internal medicine
Diabetes mellitus
Natriuretic Peptide
Brain
medicine
Humans
Hypoglycemic Agents
Sorbitol
In patient
Sodium-Glucose Cotransporter 2 Inhibitor
Prospective Studies
Sodium-Glucose Transporter 2 Inhibitors
Aged
Original Research
Heart Failure
hypertrophy/remodeling
business.industry
Luseogliflozin
Editorials
Stroke Volume
Hypertrophy
Middle Aged
medicine.disease
sodium-glucose cotransporter 2 inhibitor
Editorial
Diabetes Mellitus
Type 2
B-type natriuretic peptide
Heart failure
diabetes mellitus
Cardiology
Female
diastolic dysfunction
Cardiology and Cardiovascular Medicine
Cotransporter
business
Heart failure with preserved ejection fraction
diabetic diastolic heart failure
Biomarkers
Inositol
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
ISSN: 2047-9980
Popis: Background Effects of sodium‐glucose cotransporter 2 inhibitors on reducing hospitalization for heart failure have been reported in randomized controlled trials, but their effects on patients with heart failure with preserved ejection fraction ( HF p EF ) are unknown. This study aimed to evaluate the drug efficacy of luseogliflozin, a sodium‐glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus and HF p EF . Methods and Results We performed a multicenter, open‐label, randomized, controlled trial for comparing luseogliflozin 2.5 mg once daily with voglibose 0.2 mg 3 times daily in patients with type 2 diabetes mellitus suffering from HF p EF (left ventricular ejection fraction >45% and BNP [B‐type natriuretic peptide] concentrations ≥35 pg/mL) in a 1:1 randomization fashion. The primary outcome was the difference from baseline in BNP levels after 12 weeks of treatment between the 2 drugs. A total of 173 patients with diabetes mellitus and HF p EF were included. Of these, 83 patients were assigned to receive luseogliflozin and 82 to receive voglibose. There was no significant difference in the reduction in BNP concentrations after 12 weeks from baseline between the 2 groups. The ratio of the mean BNP value at week 12 to the baseline value was 0.79 in the luseogliflozin group and 0.87 in the voglibose group (percent change, −9.0% versus −1.9%; ratio of change with luseogliflozin versus voglibose, 0.93; 95% CI, 0.78–1.10; P =0.26). Conclusion In patients with type 2 diabetes mellitus and HF p EF , there is no significant difference in the degree of reduction in BNP concentrations after 12 weeks between luseogliflozin and voglibose. Registration URL : https://www.umin.ac.jp/ctr/index.htm ; Unique identifier: UMIN 000018395.
Databáze: OpenAIRE
Externí odkaz: